Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504–11. In the Materials and Methods section, fifth paragraph, this sentence should read as follows:
A minimal clinically important difference (MCID) in HAQ-DI was defined as a change from baseline of ≤−0.22. [Not ≥−0.22.]
We regret the error.
